GleamWall
中文EN

GTBP GT Biopharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 109657 · Fiscal year ends 12/31

Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-309.0%
TTM EPS YoY-14.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,446.5%
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets—
Debt / equity0.00x
Current ratio4.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.28x
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$3.47M$5.80M
SG&A expense$8.95M$8.57M
Operating income-$12.42M-$14.36M
Interest expense$127,000—
Net income-$28.35M-$13.16M
EPS (basic)-6.68-6.94
EPS (diluted)-6.68-6.94
Weighted avg. shares (diluted)5.51M1.90M
Balance sheet
Cash & equivalents$6.81M$4.04M
Current assets$8.11M$4.23M
Total assets$8.11M$4.23M
Current liabilities$2.32M$5.90M
Total liabilities$2.32M$5.90M
Shareholders' equity$5.79M-$1.67M
Shares outstanding1.02M2.23M
Cash flow statement
Operating cash flow-$12.91M-$12.90M
Investing cash flow—$12.89M
Financing cash flow$15.78M$2.98M
Stock-based compensation$432,000$230,000
Dividends paid$229,000—

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.